Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 8/20 | 0.67 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.55 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL171588 | 0.88 | PIK3CG (0.67) | PIK3CGPIK3CDJAK2RAD52RECQL | |
| SCHEMBL10086558 | 0.78 | PIK3CG (0.77) | PIK3CGPIK3CDJAK2CFTR | |
| SCHEMBL608796 | 0.78 | PIK3CG (0.66) | PIK3CGCHRNB2CHRNA4RAD52RECQL | |
| SCHEMBL10085390 | 0.78 | PIK3CG (0.80) | PIK3CGPIK3CDJAK2CHRNB2CHRNA4 | |
| SCHEMBL10085393 | 0.77 | PIK3CG (0.79) | PIK3CGPIK3CDJAK2CHRNB2CHRNA4 | |
| SCHEMBL10085376 | 0.76 | PIK3CG (0.77) | PIK3CGPIK3CDJAK2 | |
| SCHEMBL10085391 | 0.76 | PIK3CG (0.76) | PIK3CGPIK3CDJAK2 | |
| SCHEMBL10085383 | 0.75 | PIK3CG (0.78) | PIK3CGPIK3CDJAK2CFTR | |
| SCHEMBL10085384 | 0.75 | PIK3CG (0.75) | PIK3CGPIK3CDJAK2 | |
| SCHEMBL10085369 | 0.75 | PIK3CD (0.79) | PIK3CGPIK3CDJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120039849-A1 | TETRAHYDROTHIAZOLOPYRIDINE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2010096389-A1 | TETRAHYDROTHIAZOLOPYRIDINE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120039849-A1 | TETRAHYDROTHIAZOLOPYRIDINE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CA, PIK3CD, PIK3CG | PIK3CG 3/4885PIK3CD 2/4885JAK2 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.